SCHEMBL5124135

SCHEMBL5124135

Cc1cc(C)n2c(NCC3CCCCC3)c(-c3ccc(C#Cc4ccccc4)s3)nc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ADORA3 P0DMS8 1/20 0.34
PKM P14618 1/20 0.32
PKLR P30613 1/20 0.32
APP P05067 1/20 0.32
GRM5 P41594 4/20 0.32
ALDH1A1 P00352 4/20 0.32
GAA P10253 3/20 0.32
KDM4E B2RXH2 3/20 0.32
MAPT P10636 3/20 0.32
RAB9A P51151 2/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CREBBP Q92793 2/20 0.31
POLB P06746 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
NPC1 O15118 1/20 0.31
BRD4 O60885 1/20 0.30
PDE5A O76074 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119818 0.90 PKM (0.41) MEN1KMT2AADORA3PKMPKLR
SCHEMBL5129074 0.86 GAA (0.46) PKMPKLRALDH1A1GAAKDM4E
SCHEMBL5116936 0.83 NR1H4 (0.44) ALDH1A1GAANR1H4
SCHEMBL5120861 0.80 MAPT (0.35) MEN1KMT2APKMPKLRALDH1A1
SCHEMBL5127369 0.80 NR1H4 (0.41) PKMPKLRALDH1A1GAAKDM4E
SCHEMBL5124139 0.79 GRM5 (0.33) PKMGRM5ALDH1A1SMN1; SMN2
SCHEMBL5128541 0.78 GAA (0.46) MEN1KMT2AADORA3PKMALDH1A1
SCHEMBL5122706 0.78 CDK9 (0.41) MEN1KMT2AALDH1A1GAAKDM4E
SCHEMBL5122911 0.78 NR1H4 (0.44) MEN1KMT2AADORA3APPALDH1A1
SCHEMBL5122899 0.78 NR1H4 (0.42) PKMPKLRGRM5GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS MEN1 1791/4885KMT2A 1107/4885ADORA3 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.